+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Latin America Bladder Cancer Therapeutics & Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987284
  • Report
  • February 2020
  • Region: Latin America
  • 100 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Johnson and Johnson
Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. As per the data from the World Health Organization (2018), the number of new cases of Bladder cancer in Brazil was 9,127 which is around 3.3% of the total cancers that occurred in 2018.

In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Latin America. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.

Hence, the increasing awareness about bladder cancer and related therapies, the Latin America bladder cancer therapeutics and diagnostics market is expected to grow in the coming future. Apart from this, factors like increasing healthcare expenditure and innovations in novel drug development are also contributing to the growth of this market.

Key Market Trends

Radiation Therapy is Expected to Cover a Large Share of the Market

Bladder cancer is highly prevalent and increases with age. As per a 2016 report by Cancer Research UK, the incidence of bladder cancer increases with age. Moreover, the geriatric population in Latin America countries is expected to increase in the future as per a 2017 report by the United Nations titled "World Population Ageing" 2017. This factor is expected to increase the number of bladder cancer patients in future.

The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.

Competitive Landscape

The Latin America bladder cancer market is moderately competitive and majorly dominated by the global players. With the rising technology and focus of various companies on the drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Johnson and Johnson

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
4.2.2 Increasing Healthcare Expenditure
4.2.3 Innovations in Drug Development
4.3 Market Restraints
4.3.1 Rise in the number of Patent Expirations
4.3.2 Asymptomatic Nature of the Disease
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Other Rare Types
5.2 By Therapeutics and Diagnostics
5.2.1 By Therapeutics
5.2.1.1 Chemotherapy
5.2.1.2 Immunotherapy
5.2.1.3 Radiation Therapy
5.2.1.4 Surgery
5.2.2 By Diagnostics
5.2.2.1 Cytoscopy
5.2.2.2 Biopsy
5.2.2.3 Urinalysis
5.2.2.4 Urine Ctyology
5.2.2.5 Bladder Ultrasound
5.3 Geography
5.3.1 Latin America (LATAM)
5.3.1.1 Mexico
5.3.1.2 Brazil
5.3.1.3 Argentina
5.3.1.4 Rest of Latin America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca Plc.
6.1.2 Bristol Myers Squibb
6.1.3 Celgene Corporation
6.1.4 Eli Lilly and Co.
6.1.5 GlaxoSmithKline Plc.
6.1.6 Merck & Co., Inc.
6.1.7 Johnson and Johnson
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi S.A.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...